Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB1 | Q9Y478 | 17/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 16/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 13/20 | 0.66 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.47 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.47 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.47 |
| ▸ | TFDP2 | Q14188 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25735807 | 0.94 | PRKAB1 (0.89) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 | |
| SCHEMBL2544579 | 0.89 | PRKAB1 (0.80) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 | |
| SCHEMBL2544583 | 0.88 | PRKAB1 (0.78) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 | |
| SCHEMBL12266521 | 0.86 | PRKAB1 (0.75) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 | |
| SCHEMBL14823320 | 0.86 | PRKAB1 (0.75) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 | |
| SCHEMBL12241831 | 0.86 | PRKAB1 (0.75) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 | |
| SCHEMBL12241788 | 0.85 | PRKAB1 (0.75) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 | |
| SCHEMBL2546151 | 0.85 | PRKAB1 (0.73) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 | |
| SCHEMBL12241666 | 0.84 | PRKAG1 (0.72) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 | |
| SCHEMBL2545108 | 0.82 | PRKAB1 (0.70) | PRKAB1PRKAG1PRKAA1PRKAA2PRKAG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230117831-A1 | MULTI-FUNCTIONAL CHIMERIC MOLECULES | THE BROAD INSTITUTE, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-2348857-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2348857-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-8410284-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410284-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410284-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-04-02 | — | — | US | disclosed |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| WO-2010047982-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | PRKAB1 5/4885PRKAG1 2/4885PRKAA1 13/4885 |
| US-20230117831-A1 | MULTI-FUNCTIONAL CHIMERIC MOLECULES | PHAX, PAICS, SARS1 | PRKAB1 2161/4885PRKAG1 1292/4885PRKAA1 506/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | PRKAB1 2744/4885PRKAG1 1921/4885PRKAA1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.